<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2015043</article-id><article-id pub-id-type="pmcid-ver">PMC2015043.1</article-id><article-id pub-id-type="pmcaid">2015043</article-id><article-id pub-id-type="pmcaiid">2015043</article-id><article-id pub-id-type="pmid">10848719</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00217.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Population Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kerbusch</surname><given-names initials="T">T</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huitema</surname><given-names initials="ADR">A D R</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ouwerkerk</surname><given-names initials="J">J</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Keizer</surname><given-names initials="HJ">H J</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Math&#244;t</surname><given-names initials="RAA">R A A</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schellens</surname><given-names initials="JHM">J H M</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beijnen</surname><given-names initials="JH">J H</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au3">3</xref></contrib><aff id="au1"><label>1</label><institution>Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute</institution><addr-line>Amsterdam, The Netherlands</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Clinical Oncology, Leiden University Medical Center</institution><addr-line>Leiden, The Netherlands</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Medical Oncology, The Netherlands Cancer Institute</institution><addr-line>Amsterdam, The Netherlands</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Dr T. Kerbusch, Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.</corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2000</year></pub-date><volume>49</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">151585</issue-id><fpage>555</fpage><lpage>561</lpage><history><date date-type="received"><day>15</day><month>7</month><year>1999</year></date><date date-type="accepted"><day>08</day><month>3</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:38:20.863"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0049-0555.pdf"/><abstract><sec><title>Aims</title><p>This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m<sup>&#8722;2</sup> ifosfamide by means of a 72 h continuous i.v. infusion.</p></sec><sec sec-type="methods"><title>Methods</title><p>A model was developed using nonlinear mixed effects modelling (NONMEM) to describe the nonlinear pharmacokinetics of ifosfamide by linking the ifosfamide plasma concentrations to the extent of the autoinduction.</p></sec><sec><title>Results</title><p>The proposed model revealed the effect of autoinduction on the disposition of ifosfamide. The initial clearance, volume of distribution, rate constant for enzyme degradation, induction half-life of the enzyme and the ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation were estimated at 2.94 &#177; 0.27 l h<sup>&#8722;1</sup>, 43.5 &#177; 2.9 l, 0.0546 &#177; 0.0078 h<sup>&#8722;1</sup>, 12.7 h and 30.7 &#177; 4.8 &#181;<sc>m</sc>, respectively. Interindividual variabilities of initial clearance, volume of distribution, rate constant for enzyme degradation were 24.5, 23.4 and 22.7%, respectively. Proportional and additive variability not explained by the model were 13.6% and 0.0763 &#181;<sc>m</sc>, respectively.</p></sec><sec><title>Conclusions</title><p>The absence of a lag time for the autoinduction of ifosfamide metabolism could be the result of an immediate inhibition of the enzymatic degradation of CYP3A4 by ifosfamide. By application of the autoinduction model individual pharmacokinetic profiles of patients were described with adequate precision. This model may therefore be used in the future development of a model to individualize dose selection in patients.</p></sec></abstract><kwd-group><kwd>autoinduction</kwd><kwd>ifosfamide</kwd><kwd>NONMEM</kwd><kwd>population pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>